北 京 大 成 （ 南 京 ） 律 师 事 务 所 关 于 常 州 千 红 生 化 制 药 股 份 有 限 公 司 2 024 年 第 二 次临时 股 东 大 会 的 法 律 意 见 书 北 京 大 成 （ 南 京 ） 律 师 事 务 所 南京市鼓楼区集慧路 18 号联创科技大厦 A 座 7-11 楼 联系电话：028-83755000 传真：025-83755111 邮编：210036 北京大成（南京）律师事务所关于常州千红生化制药股份有限 公司 2024 年第二次临时股东大会的法律意见书 致：常州千红生化制药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公 司股东大会规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律、法 规和其他有关规范性文件的要求，北京大成（南京）律师事务所（以下简称"本 所"）接受常州千红生化制药股份有限公司（以下简称"公司"）的委托，指派 律师参加公司 2024 年第二次临时股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开 ...

2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 特别提示： 证券代码：002550 证券简称：千红制药 公告编号：2024-043 常州千红生化制药股份有限公司 1、本次股东大会未出现否决提案的情形。 2、网络投票时间：2024 年 11 月 5 日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 11 月 5 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 11 月 5 日 上午 9:15 至下午 15:00 期间的任意时间。 （二）召开地点：公司云河路厂区二楼会议室（江苏省常州市新北区云河路 518 号） （三）召开方式：现场与网络会议方式 （四）召集人：公司董事会 （五）主持人：公司副董事长赵刚先生 2、本次股东大会不涉及变更以往股东大会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2024 年 11 月 5 日（周二）下午 15:00 同意 92,523,367 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-042 公司于 2019 年 8 月 29 日分别召开了第四届董事会第十五次会议、第四届监 事会第十四次会议，于 2019 年 9 月 25 日召开了 2019 年第一次临时股东大会， 审议通过了《公司第一期员工持股计划（草案）及其摘要的议案》等相关议案， 具体内容详见公司于 2019 年 8 月 30 日、2019 年 9 月 26 日在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 公司于 2020 年 3 月 31 日收到中国证券登记结算有限责任公司深圳分公司下 发的《证券过户登记确认书》，公司回购专用证券账户中的 5,999,999 股公司股票 非交易过户至员工持股计划专用证券账户，占公司总股本的 0.469%，过户价格 为 2.8 元/股，转让总金额为 16,799,997.2 元，所受让的标的股票的锁定期为 36 个月，续存期为不超过 48 个月。具体内容详见公司 2020 年 4 月 2 日披露于巨潮 资讯网（www.cninfo.com.cn）的《关于第一期员工持股计划实施进展暨股票过户 完成的公告》（公告编号 ...

公 司 研 究 医 药 生 物 [Table_Reportdate] 2024年10月22日 公 司 简 评 [Table_invest] 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn 联系人 付婷 futing@longone.com.cn | --- | --- | |--------------------------|-----------| | | | | 收盘价 | 6.45 | | 总股本 ( 万股 ) | 127,980 | | 流通 A 股 /B 股 ( 万股 ) | 91,023/0 | | 资产负债率 (%) | 10.04% | | 市净率 ( 倍 ) | 3.32 | | 净资产收益率 ( 加权 ) | 12.80 | | 12 个月内最高 / 最低价 | 7.18/4.20 | [Table_QuotePic] -20% -9% 2% 12% 23% 34% 45% 55% 23-10 2 ...

证券代码：002550 证券简称：千红制药 常州千红生化制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | |-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

公 司 季 报 点 评 证 券 研 究 报 告 公 司 报 告 24Q3利润端增长持续，并购方圆收获潜力大单品 千红制药(002550.SZ) | --- | --- | |----------------------------|-----------------| | | | | 主要数据 | | | 行业 | 医药 | | 公司网址 | www.qhsh.com.cn | | 大股东 / 持股 | 王耀方 /19.96% | | 实际控制人 | 王耀方 | | 总股本 ( 百万股 ) | 1,280 | | 流通 A 股 ( 百万股 ) | 910 | | 流通 B/H 股 ( 百万股 ) | | | 总市值（亿元） | 78 | | 流通 A 股市值 ( 亿元 ) | 56 | | 每股净资产 ( 元 ) | 1.93 | | 资产负债率 (%) | 10.0 | | 行情走势图 | | 推荐（维持） 相关研究报告 【平安证券】千红制药（002550.SZ）*首次覆盖报告* 肝素供需格局持续改善，有望开启快速增长新周期*推 荐20231219 【平安证券】千红制药（002550.SZ）*半年报点评*利 ...

Investment Rating - The report maintains a "Buy" rating for Qianhong Pharmaceutical, indicating an expected stock price increase of over 20% relative to the market benchmark within the next six months [11]. Core Insights - Qianhong Pharmaceutical's revenue for Q1-Q3 2024 was 1.21 billion yuan, a year-on-year decrease of 17.6%, while the net profit attributable to shareholders increased by 56.5% to 310 million yuan [1][2]. - The company has announced the acquisition of Changzhou Fangyuan for 390 million yuan, which is expected to enhance its product line, particularly with the addition of the core product, Sulbactam Ertapenem, a new drug with good market positioning [2]. - The gross profit margin has shown continuous improvement, reaching 57.2% in Q3 2024, up 11.4 percentage points year-on-year [1][2]. Financial Performance - For Q3 2024, Qianhong achieved a revenue of 350 million yuan, a 14% decline year-on-year, but the net profit attributable to shareholders rose by 60.9% to 130 million yuan [1]. - The company’s gross profit margin for the last four quarters was 44.7%, 53.1%, 52.2%, and 57.2%, indicating a significant upward trend [1]. - The projected net profits for 2024-2026 are 390 million, 460 million, and 460 million yuan respectively, with corresponding P/E ratios of 20, 17, and 17 [2][3]. Acquisition Details - Qianhong plans to acquire all equity of Fangyuan Pharmaceutical through a bankruptcy restructuring process, with an initial deposit of 20 million yuan and the remaining 370 million yuan to be paid upon fulfillment of all conditions [2]. - The acquisition is expected to leverage regional advantages as both companies are located in close proximity in Changzhou [2]. Innovation Pipeline - Qianhong has two innovative drugs currently in Phase II clinical trials, with one targeting acute myeloid leukemia and another for ischemic stroke, both showing promising safety and efficacy results [2].

Core Viewpoint - Company has recovered part of the settlement amount of 85 million yuan after five years of issues with Anxin Trust, which significantly impacted its financial performance in the third quarter of the year [1] Financial Performance - For the first three quarters of the year, the company reported revenue of 1.208 billion yuan, a year-on-year decrease of 17.62%, primarily due to a decline in the export prices of raw material orders [1] - The net profit attributable to shareholders reached 310 million yuan, a year-on-year increase of 56.47%, mainly due to improved gross profit margins and the recovery of part of the bad debt provision from Anxin Trust [1] - In the third quarter, the company achieved revenue of 352 million yuan, a year-on-year decrease of 13.97%, while the net profit attributable to shareholders was 127 million yuan, a year-on-year increase of 60.84% [1] Settlement with Anxin Trust - The company reached a settlement with Jianyuan Trust regarding the Ruiying 64 Trust Plan, receiving 85 million yuan, which is 50% of the principal amount of 170 million yuan [1] - The company has submitted a withdrawal application to the Shanghai Financial Court regarding the case, and the court has approved the withdrawal [1] - The 85 million yuan settlement contributed approximately 67% of the company's net profit in the third quarter [1] Acquisition of Fangyuan Pharmaceutical - The company has signed an agreement to participate in the bankruptcy reorganization of Fangyuan Pharmaceutical, planning to acquire 100% of its equity for 390 million yuan [3] - The reorganization will retain Fangyuan Pharmaceutical's legal entity status while separating non-restructurable assets [3] - Fangyuan Pharmaceutical's core product, Sulbactam, is a new generation semi-synthetic aminoglycoside antibiotic with significant market potential and limited competition [3]

Investment Rating - The report maintains a "Buy" rating for Qianhong Pharmaceutical [1] Core Views - The company reported a net profit attributable to shareholders of 310 million yuan for the first three quarters of 2024, representing a year-on-year increase of 56.47%. The net profit for Q3 alone was 127 million yuan, up 60.84% year-on-year, significantly exceeding expectations [2] - Qianhong Pharmaceutical plans to acquire all shares of Fangyuan Pharmaceutical for 390 million yuan, aiming to enhance its product portfolio and profitability [2] - The company has increased its R&D expenses significantly in Q3, which impacted its non-recurring net profit. However, the clinical trial results for its innovative drug QHRD107 are expected to be positive [2] - The recovery of 85 million yuan from a trust settlement is expected to further boost the company's profits [2] - The profit forecasts for 2024-2026 have been revised upwards due to the expected benefits from the acquisition and the trust settlement, with projected net profits of 380 million, 401 million, and 445 million yuan respectively [2] Financial Summary - Total revenue for 2023 is projected at 1.814 billion yuan, with a decline of 21.24% year-on-year, while the net profit for 2023 is expected to be 181.86 million yuan, down 43.77% year-on-year [1][8] - The earnings per share (EPS) for 2024 is estimated at 0.30 yuan, with a price-to-earnings (P/E) ratio of 20.54 based on the current market price [1][9] - The company’s total assets are projected to reach 2.803 billion yuan by 2024, with a debt-to-asset ratio of 9.56% [8][9]

证券代码：002550 证券简称：千红制药 公告编号：2024-036 常州千红生化制药股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）第六届 董事会第六次会议通知于 2024 年 10 月 8 日通过邮件方式送达，会议于 2024 年 10 月 17 日在公司会议室召开，会议应出席董事 9 人，实际出席董事 9 人。会议 由董事长王耀方先生召集并主持，公司监事、高级管理人员等应邀人员列席会议。 本次会议的通知、召开以及董事出席人数和表决人数符合《公司法》等法律法规 和本公司《公司章程》的有关规定，本次会议所形成的有关决议合法、有效。 本次董事会会议形成决议如下： 一、审议并通过了《公司 2024 年第三季度报告的议案》 表决结果：9 票同意，0 票弃权，0 票反对，议案获得通过。 《常州千红生化制药股份有限公司 2024 年第三季度报告》详见信息披露媒 体：巨潮资讯网 www.cninfo.com.cn 和 2024 年 10 月 18 日的《证券时报》 ...